Form 4: VYNE Therapeutics Inc. Executive Reports Tax Withholding
SEC Form 4 Filing
Mutya Harsch, Chief Legal Officer and GC of VYNE Therapeutics Inc., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On September 30, 2024, Mutya Harsch, Chief Legal Officer and GC of VYNE Therapeutics Inc., reported a transaction involving common stock.
- The transaction involved the withholding of 105 shares to satisfy tax withholding requirements related to the vesting of restricted stock units.
- Following the transaction, Harsch directly owns 149,026 shares of VYNE Therapeutics Inc.
Sentiment
Score: 5
Explanation: This is a routine filing related to tax withholding, so it has a neutral sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is important for investor confidence.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard tax withholding procedure.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of transaction (tax withholding). |
| 10/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.